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Abstract
Setting: Mumbai, India. A study conducted in Mumbai two decades ago revealed the extent of inappropriate tuberculosis
(TB) management practices of private practitioners. Over the years, India’s national TB programme has made significant
progress in TB control. Efforts to engage private practitioners have also been made with several successful documented
public-private mix initiatives in place.
Objective: To study prescribing practices of private practitioners in the treatment of tuberculosis, two decades after a
similar study conducted in the same geographical area revealed dismal results.
Methods: Survey questionnaire administered to practicing general practitioners attending a continuing medical education
programme.
Results: The participating practitioners had never been approached or oriented by the local TB programme. Only 6 of the
106 respondents wrote a prescription with a correct drug regimen. 106 doctors prescribed 63 different drug regimens.
There was tendency to over treat with more drugs for longer durations. Only 3 of the 106 respondents could write an
appropriate prescription for treatment of multidrug-resistant TB.
Conclusions: With a vast majority of private practitioners unable to provide a correct prescription for treating TB and not
approached by the national TB programme, little seems to have changed over the years. Strategies to control TB through
public sector health services will have little impact if inappropriate management of TB patients in private clinics continues
unabated. Large scale implementation of public-private mix approaches should be a top priority for the programme.
Ignoring the private sector could worsen the epidemic of multidrug-resistant and extensively drug-resistant forms of TB.
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Introduction
Two decades ago, a study assessing TB management practices
of private medical doctors was conducted at Dharavi, one of Asia’s
most densely populated slums located in Mumbai, India[1].
Revealing that 100 practitioners had prescribed 80 different drug
regimens for treatment of TB, the study highlighted the magnitude
of the poor prescribing practices of private medical practitioners.
The study also seemed to help stimulate national and global efforts
to educate and engage such practitioners in TB control[2,3,4].
India’s Revised National Tuberculosis Control Programme
(RNTCP) has made significant progress in TB control over the last
decade through countrywide DOTS implementation[5,6].This
also includes efforts to engage the private medical sector in TB
care and control through various published schemes[2].Two
factors aroused our interest in exploring the change in prescribing
practices by private practitioners over the past two decades since
the original study was published. First, we found an alarming trend
of increasing incidence of multidrug-resistant (MDR-TB) among
samples sent to the laboratory at the P D Hinduja Hospital, a
modern medical centre in Mumbai[7]. The incidence of MDR-TB
among treated cases was 60 percent[8]. Secondly, this cohort of
patients had received a significant number of irrational prescrip-
tions prior to consulting our hospital. Clearly, the need for another
audit of private practitioners prescriptions for TB seemed as
pertinent as it was two decades ago. In order to understand any
changes in the TB management practices of private practitioners,
we conducted our study on private practitioners practicing in the
same geographical area.
Materials and Methods
The study was carried out among private practitioners
practicing at Dharavi, a large slum in Mumbai. Dharavi covers
an area of approximately 1.75 sq. kilometers, and has a population
of over 2.5 million. A list of all private medical practitioners
practicing in the area was compiled from those available with the
local medical association and representatives of drug companies.
The practitioners belonged to and practiced different systems of
medicine. The Hinduja hospital regularly offers Continuing
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listed practitioners were invited for a CME session on manage-
ment of tuberculosis at a venue close to the slum area.
Participation was voluntary and no incentives were offered for
participation. Prior to the beginning of the CME session, a short
questionnaire was handed out to each of the attending
practitioners. Besides seeking general information related to their
private practice, a main question posed to private practitioners was
identical to the one asked in the original study
1 (‘‘Please write a
prescription for a previously untreated adult case of sputum-positive pulmonary
tuberculosis weighing 50 kg’’). In addition, a question was also posed
to understand their prescribing practices in the treatment of MDR
TB (‘‘Please write a prescription for a previously untreated adult case of
multidrug-resistant tuberculosis resistant to isoniazid and rifampicin and
weighing 50 kg’’). The practitioners were expected to write a
prescription and specify drugs, dosage and duration of treatment
in three columns provided. The prescriptions written by the
practitioners were then analyzed and compared for appropriate-
ness with those recommended nationally and international-
ly[9,10].The prescribing practices were also compared with those
reported in the study published in 1991[1].
Results
Of the 150 physicians listed and invited for the CME, 106
attended it and all of them consented to participate in the study. 46
practitioners were qualified to practice western medicine and are
referred to here as allopaths while 60 were trained in one of the
alternative systems of medicine—homeopathy, ayurveda or
unani—and are referred to here as non-allopaths. Their training
background regardless, 26 (44%) of the non-allopathic physicians
admitted that they practiced mainly Western medicine in their
clinics. Most participating physicians had over five years in clinical
practice and the median number of TB patients seen per month by
a practitioner was eight. Only 20 of the 104 respondents claimed
to be using drugs from alternative systems of medicine in the
treatment of TB in addition to the modern drugs. A third of
responding practitioners said they referred their TB patients to
government services for treatment. Table 1 gives a summary of
other details of the participating private practitioners.
In response to the question on the prescription they would write
for a new adult patient with drug-susceptible TB, only 6 of the 106
respondents prescribed what could be considered an appropriate
drug regimen with correct drugs, dosage and duration. Overall,
106 doctors prescribed 63 different drug regimens for treatment of
TB. No practitioner prescribed intermittent drug regimen
currently recommended by the RNTCP. The various regimens
prescribed by the physicians are summarized in Table 2. There
were no significant differences between the prescriptions offered by
doctors trained in Western medicine and those trained in
alternative systems (Table 3). However, significant differences
were observed when the prescriptions for the treatment of drug
susceptible TB were compared with those reported in the 1991
study. If only those regimens with four anti-TB drugs in the
intensive phase and a total duration of minimum six and
maximum eight months duration were considered appropriate, a
significantly higher proportion of prescriptions in the current study
were appropriate compared to the 1991 study (47% against 13%,
p-value,0.001). Over a half of all prescriptions in this study were
still inappropriate however.
In response to the question on a prescription for a patient
known to be suffering from MDR-TB, there were even more
discrepancies. These are summarized in Table 4. Only 5 of the
106 respondents could write an appropriate prescription with a
minimum of 3 new second line- drugs in the right doses for a
minimum recommended duration of 18 months. 13 returned
prescriptions that continued first line drugs without adding any
second line drugs, 25 returned blank prescriptions in response to
this question and 35 of respondents added a single second line
drug. In 70% of the prescriptions, this was a fluoroquinolone.
Discussion
India accounts for about one-fifth of the global burden of
TB[6]. The DOTS-based RNTCP has been remarkably successful
in achieving the global targets of detecting 70% of the estimated
TB cases and curing 85% of them[5,6]. In spite of a significantly
strengthened TB programme and the progress made, 50–80% of
TB patients in India still seek care at private clinics and TB
treatment offered in the private health sector remains substan-
dard[11,12,13]. A study conducted at our hospital among TB
patients, not exposed to TB services offered in the public sector,
found 170 out of 200 patients interviewed (85%) to be unaware of
the DOTS programme.[14].This is further evident from the fact
that out of the total market of USD 94 million for the first-line
anti-TB medicines in India, the public sector purchases drugs
worth USD 24 million while the private sector accounts for the
remaining USD 61 million[15].
Table 1. Demographics and practice details.
Number of
physicians
Number of years
in practice
#51 7
6–15 35
16–25 17
$25 30
No response 7
Number of new TB
patients seen every
month?
,19
1–5 64
6–10 20
11–20 3
.20 3
No response 7
Use drugs of alternative
systems of medicine
to treat TB?
Yes 20
No 84
No response 2
Information source to
update knowledge on
TB management
Books 25
Internet 19
CMEs 43
Journals 28
Pharmaceutical
representatives
25
doi:10.1371/journal.pone.0012023.t001
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health sector in general and private practitioners in particular in
TB care and control[2,16]. Based on numerous successful projects
with documented evidence on feasibility, effectiveness and cost-
effectiveness[17,18], the RNTCP has designed and promoted
public-private mix schemes that define the input of the public
sector and expectations from the private sector and offer financial
and non-financial incentives[2]. Several thousands of private
practitioners as well as non-governmental organizations are
reported to have been collaborating under the various schemes[5].
However, they comprise only a miniscule of the large private
sector in the country and their precise contribution to detecting
and treating TB cases is not known.
In the 1991 study of prescribing behaviour of private
practitioners, 100 doctors reported to have provided 80 different
prescriptions[1]. A similar study undertaken in Mumbai and rural
Pune, a neighbouring district and published in 1998, reported 105
private practitioners giving 79 diverse prescriptions[11] and in this
study, 106 doctors wrote 63 different prescriptions. Can this be
called progress? An analysis of the prescriptions may provide some
measure of consolation. Seventy three doctors used four-drug fixed
dose combinations and 53 wrote prescriptions of drugs for longer
than six months suggesting an overkill rather than under-
treatment of their TB patients. If the patients did take their
medicines as prescribed and did adhere to treatment, a large
majority were less likely to develop multidrug-resistance. However,
the above referred study that followed up patients diagnosed in the
private sector showed that patients did not generally take all the
medicines as prescribed by their doctors and that their treatment
completion rates were very poor[11].
We extended the senior author’s original study by also auditing
the prescriptions of the same group of physicians for MDR-TB.
There were several reasons for doing this. The prevalence of
MDR-TB has clearly grown significantly in India over the last two
decades, accounting for 20% of the global MDR-TB cases
reported in 2006[19]. The actual levels of MDR-TB may be
much higher than those projected by national estimates as the
patients diagnosed and managed in the private sector never get
reported. A recent study in Mumbai found prevalence rates of
MDR TB to be 24% among newly diagnosed, previously
untreated patients and rates of 41% among first-line drug
failures[20].
Poor prescribing practice is a major factor fuelling the MDR-
TB epidemic. A report from Mumbai showed that about 10% of
all MDR-TB cases were XDR-TB[21]. The quality of prescrip-
tions for MDR-TB was even more dismal than those for drug-
susceptible TB. Only 5 of the 106 respondents could write an
appropriate prescription with a minimum of 3 new second-line
drugs in the right doses for a right duration.
Over a third of respondents added a single second-line drug
only, this single drug being a fluoroquinolone in 70% of such
Table 2. Drug regimens prescribed by private practitioners.
*
HRE 6 2
HREZ 2 4
HREZ 3 3
HREZ 5 1
HREZ 6 34
HREZ 7 3
HREZ 8 10
HREZ 9 21
HREZ 10 1
HREZ 12 3
HREZ not mentioned 2
SHRE 18 1
SHREZ 6 2
SHREZ 8 2
SHREZ 9 5
SHREZ 12 1
SHREZ not mentioned 2
HREZ+Levofloxacin 8 3
HREZ+Levofloxacin 9 1
No response — 5
*Abbreviations used for drugs prescribed: S- Streptomycin, H- Isoniazid, R-
Rifampicin, E – Ethambutol, Z – Pyrazinamide.
doi:10.1371/journal.pone.0012023.t002
Table 3. Comparison between prescriptions of allopaths and physicians trained in alternative forms of medicine.
PARAMETER COMPARED Allopath Non-allopath Not mentioned
Correct prescription 42
Drug formulations reported to be used:
Separate drugs 6 3
2-drug Fixed Dose Combinations 0 2
3-drug Fixed Dose Combinations 2 2
4-drug Fixed Dose Combinations 32 40 1
No response 6 11 1
Prescription of Streptomycin 67
Adequate duration (6 months) 19 18 1
Shorter duration(less than 6 months) 26
Longer duration (more than 6 months) 25 25 1
Duration not mentioned 36
Use of Levofloxacin 31
doi:10.1371/journal.pone.0012023.t003
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center reported 30% of all MTB cultures to be fluoroquinolone
resistant[22]. This combination of MDR and additional fluoro-
quinolone resistance — pre-XDR TB — is a direct result of
inappropriate and indiscriminate fluoroquinolone use. A majority
of the prescriptions reported by the practitioners would serve only
to amplify resistance.
An important limitation of this follow up study, especially with
regards to its comparability with the original study, needs to be
acknowledged. The original 1991 study was a one-on-one study
conducted among a randomly selected cohort of 143 physicians
chosen from a list of 287 physicians, while the present study used a
CME session for the purpose. This may have introduced a
‘‘volunteer bias’’ with a likelihood of only those doctors who
needed to update their knowledge or those who had the time
available attending the CME. However, to our knowledge, the
doctors attending CMEs offered regularly at our hospital, is always
a mix of not only those seeking to gain new knowledge but also the
‘‘good and regular’’ ones wishing to keep their knowledge up-to-
date. It includes doctors with large as well as small practices. Also,
our conducting CMEs generally on a Sunday facilitates attendance
of doctors who are otherwise busy with their practices on week
days. Furthermore, conducting one-to-one interviews with prac-
ticing doctors is much more time and resource intensive than it
perhaps was two decades ago. Finally, even if we restrict the
comparability of the two studies to simply drawing a sample of
doctors from the same geographical area with predominantly slum
population and a very high prevalence of TB, the findings are still
worrisome and demand attention of all those concerned with TB
control in the city and the country. Another limitation of this
study, as it was of the original study, is that what the doctors
reported could only be said to reflect their knowledge and not
necessarily their practices.
It may be unreasonable to expect the RNTCP to effectively
reach hundreds of thousands of practicing doctors. At the same
time, continued mismanagement of TB and MDR-TB patients by
private practitioners despite efforts to engage them can potentially
undo all the efforts and achievements of RNTCP. How can this
worrisome situation be addressed? Training and orientation of
practicing doctors by both RNTCP experts and private chest
physicians who believe in evidence-based practice is of course
essential but may not be sufficient. Some of the recommendations
of a recent joint monitoring mission of the RNTCP are also worth
reiterating. They include reviewing RNTCP’s current approaches
to engage the private sector in TB care and control and
redesigning them through strategic consultations with key
stakeholders such as allopathic and non-allopathic professionals’
associations and non-governmental organizations, pharmaceutical
industry, pharmacies and consumer organizations. Assessing ways
to set-up a system of mandatory notification is also recommended.
Given the magnitude of the problem of TB and MDR-TB and
the size of the private sector in India, ignoring the private sector or
dealing with it in a superficial manner cannot be an option.
Evidence from numerous successful small projects shows that local
public-private initiatives do work well[17]. Willingness on the part
of the RNTCP staff to initiate and foster collaboration is a key
requirement. A local intermediary organization acceptable to both
parties, if available, hastens the process. A logical first step that
each public sector tuberculosis unit can take would be to identify
willing practitioners and support development of a few best
practice clinics and hospitals in the private sector for management
of TB and MDR-TB. Using the private sector to help achieve
universal access to rational and standardized TB care can be a
win-win situation not only for programme managers and private
providers but also for patients with TB and people at large.
Furthermore, some thorny issues must be addressed as a priority.
Currently, the RNTCP tends to collaborate only with those
individual and institutional providers who agree to follow the
programme recommendations. As a result, those who follow
appropriate, rational, internationally recommended practices that
do not exactly match the programme guidelines cannot receive
any support or recognition from the programme. Specifically, as
the programme uses intermittent treatment regimens, physicians
using daily regimens correctly to treat their patients cannot hope
to collaborate with the programme.
Considering their large numbers and diverse backgrounds, it
would simply be not possible for the RNTCP to adequately orient,
support and supervise hundreds of thousands of private practi-
tioners. Parallel mechanisms should be developed within the
private sector to support itself to manage TB patients properly and
pass on all the relevant information essential for surveillance to the
RNTCP. This will require a combination of measures including
support to intermediary professional associations and non-
governmental institutions, promoting collaborative schemes and
introducing regulatory approaches to make standardized TB and
MDR-TB care widely accessible but only through ‘‘RNTCP-
approved’’ outlets such as the clinics of certified private
practitioners and accredited private institutions. If replacing the
TB epidemic by a MDR-TB epidemic is to be avoided, the
RNTCP will have to invest and help extend its own successes to
the private sector. Measureable progress will be possible only with
the creation of structures and staff to work with the private sector
at the national, state and district levels. Half-hearted approaches
are unlikely to make any significant change in the plethora of
treatment regimens proffered by private practitioners even after
two decades hence.
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Table 4. Analysis of the physicians’ prescriptions for MDR
TB.*
Number of second
line drugs in the
prescription
Number of
doctors
prescribing
Number of
prescriptions with
appropriate regimens
54 1
45 1
38 3
21 63
13 50
01 30
*25 prescriptions were blank.
doi:10.1371/journal.pone.0012023.t004
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